Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
OHSU Knight Cancer Institute
Alliance for Clinical Trials in Oncology
Beijing 302 Hospital
Chinese PLA General Hospital
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Medical College of Wisconsin
Centre Hospitalier Universitaire de Nice
PETHEMA Foundation
City of Hope Medical Center
Novartis
Ohio State University Comprehensive Cancer Center
Incyte Corporation
University of Nebraska
University of California, Irvine
The Methodist Hospital Research Institute
M.D. Anderson Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
Children's Oncology Group
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Institute of Hematology & Blood Diseases Hospital, China
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
First Affiliated Hospital of Zhejiang University
Fred Hutchinson Cancer Center
St. Jude Children's Research Hospital
OHSU Knight Cancer Institute
M.D. Anderson Cancer Center
Ruijin Hospital
National Cancer Institute (NCI)